Please login to the form below

Not currently logged in
Email:
Password:

Keytruda

This page shows the latest Keytruda news and features for those working in and with pharma, biotech and healthcare.

Bad news for BMS as Keytruda kidney cancer combo approved

Bad news for BMS as Keytruda kidney cancer combo approved

The Keytruda duo also cut the risk of death by 46% with those carrying the PD-L1 biomarker – and in 41% of those without. ... This represents a new treatment option for patients with advanced renal cell carcinoma, who will now have access to Keytruda

Latest news

  • Tecentriq combo shows promise in triple negative breast cancer Tecentriq combo shows promise in triple negative breast cancer

    Roche. Tecentriq's FDA approval in triple negative breast cancer will help it expand in a market dominated by Merck &Co's Keytruda. ... Keynote-552 is investigating Keytruda in combination with different chemotherapy regimens in the neoadjuvant setting

  • NICE green light for Imfinzi in groundbreaking early lung cancer treatment NICE green light for Imfinzi in groundbreaking early lung cancer treatment

    The ruling is great news for the company, as it gives Imfinzi its best chance of competing in the NSCLC market, where MSD’s Keytruda has become the overwhelmingly dominant player. ... Keytruda has marketing authorisation around the world as a

  • CHMP recommends new Keytruda dosing schedule CHMP recommends new Keytruda dosing schedule

    1 inhibitor that brought in a respectable $6.7bn year, but trailed behind Keytruda and its full year earnings of $7.2bn. ... The PD-1/PD-L1 class is a crowded one and Keytruda’s dominance hasn’t scared off new players from entering the field.

  • Keytruda adds another NSCLC approval in Europe Keytruda adds another NSCLC approval in Europe

    Squamous NSCLC completes first-line dominance. The European Commission has granted MSD's Keytruda approval in another major lung cancer setting. ... With this approval, more patients with non-small cell lung cancer may have the opportunity to benefit

  • Celgene’s Abraxane fails pancreatic cancer trial Celgene’s Abraxane fails pancreatic cancer trial

    Celgene picked up the first of these last October when Abraxane was cleared alongside Merck &Co/MSD’s Keytruda (pembrolizumab) for frontline metastatic squamous non-small cell lung cancer. ... for a breast cancer indication – and in September, the

More from news
Approximately 119 fully matching, plus 187 partially matching documents found.

Latest Intelligence

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    The cells were gene-edited to lack PD-1, the immune checkpoint targeted by drugs such as Merck &Co’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Opdivo (nivolumab), and the

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    PD-1/PD-L1 inhibitors: Keytruda is King, but the market is developing fast. ... On 28 December, Keytruda gained FDA clearance for use in Merkel cell carcinoma.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    1 inhibitor Keytruda (pembrolizumab) was backed for cancers harbouring a biomarker known as microsatellite instability-high (MSI-H). ... Merck/MSD looks to have gained a dominant position in checkpoint inhibitor immuno-oncology (IO) with Keytruda – but

  • The UK’s new five-year pricing agreement The UK’s new five-year pricing agreement

    of this include recent deals on CAR-T therapies, plus a new expansion in the use of Keytruda in lung cancer, announced late last year.

  • Is China ready for a pharmaceutical gold rush?

    Competition time. At the same time, Merck’s PD-1 agent, Keytruda, is hot on Opdivo’s heels. ... In light of recent clinical data, Keytruda is widely regarded as the better of the two checkpoint inhibitors in lung cancer.

More from intelligence
Approximately 0 fully matching, plus 16 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Attigo (part of the Mednet Group)

We are socially intuitive. Attigo deliver inspiring creative healthcare communications, whilst leading the way as partner of choice for socially-conscious...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics